D-0238-2025 Class II Ongoing
FDA drug recall D-0238-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Jan 29, 2025 and is designated Class II. Reason for recall: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. The recall status is ongoing. Affected quantity: 120,000 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 26, 2025
- Initiation Date
- Jan 29, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 120,000 bottles
Product description
Atomoxetine Capsules, USP, 10 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-755-01.
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Distribution pattern
Nationwide within the U.S
Code information
Lot Numbers: 19232356, Exp.: 5/2025; 19233198, Exp.: 7/2025; 19234213, 19234232, Exp.: 9/2025; 19241445, Exp.: 3/2026; 19243033, 19243121, Exp.: 7/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0238-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026